BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

   

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.


Recent articles from Andrii

Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers

Oct. 26, 2026      News
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers

Anthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least $100,000 with the company in the twelve months to September …

13 AI Drug Discovery Companies to Watch in 2026

June 18, 2024   
13 AI Drug Discovery Companies to Watch in 2026

AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing that its AI approach can "disrupt legacy drug discovery paradigms." …

Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows

Oct. 15, 2026      News
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows

With Science Foundries, launched today, the R&D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on a series of products Benchling has introduced throughout the year.

…

When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Oct. 10, 2026      Interviews
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: an agentic AI co-scientist that runs the company’s own …

WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Oct. 6, 2026      News
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with.

Founded in 2019 by David Del Bourgo and Julien …

Is “Rescuing Failed Drugs with AI” a Category Now?

May 22, 2026      Business Intelligence
Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million (C$216 million) at a $1 billion valuation, this …

The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Sept. 30, 2026      Business Intelligence
The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a drug candidate.

Three AI Drug Discovery Startups Raise $526 Million in Two Days

Sept. 24, 2026      News
Three AI Drug Discovery Startups Raise $526 Million in Two Days

Three AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it calls the world's largest proprietary genomic dataset. The third runs …

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

Sept. 21, 2026      Business Intelligence
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science on specific R&D workflows where the companies expect the greatest …

The Bigger Point Beyond Insilico's Aging Research Milestone

Sept. 9, 2026      Business Intelligence
The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a conventional disease indication. 

Six proteomic aging clocks were …

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.